LE WE PMID CA
Myelodysplastic syndrome1876Myelodysplastisches Syndrom

5q minus syndrome

ASXL1

Autoimmunity

Azacitidine

Bone Marrow (Pathology)

Cbl

Cell differentiation

Decitabine

Erythropoietin

GATA2

IDH1 Isocitrate dehydrogenase1 NADP soluble

IKZF1

Iron (Chelator)

Iron (Toxicology)

JAK2V617F

Lenalidomide

Leukemia (acute lymphoblastic)

Leukemia (acute myeloblastic)

Leukemia (acute myeloic)

Leukemia (chronic myelomonocytic leukaemia)

Leukemia (Juvenile myelomonocytic leukemia)

LY2157299 ttALK5

Lymphoproliferative disorders (Classification)

Lymphoproliferative disorders (Therapy related)

Mastocytosis

MPL

Myelodysplastic syndrome

Myeloproliferative syndromes

SMAD7

TET2

TGF beta

Transfusion (BASKET)

1996  
1
2008  
2
Myelodysplastic syndromes: disease overview and therapy options.
[19093333] Manag Care 17(7 Suppl 6): 3-8 (2008)
2010  
3
Myelodysplastic syndromes: a practical approach to diagnosis and treatment.
[20048028] Cleve Clin J Med 77(1): 37-44 (2010)
2007  
4
Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.
[18472976] Ther Clin Risk Manag 3(4): 553-62 (2007)
2003  
5
Molecular mechanisms of myelodysplastic syndrome.
[12810828] Jpn J Clin Oncol 33(4): 153-60 (2003)
2007  
6
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
[17366593] Cancer 109(9): 1705-14 (2007)
2006  
7
Drug therapy for myelodysplastic syndrome: building evidence for action.
[16532501] Cancer 106(8): 1650-2 (2006)
2004  
8
Novel therapies for myelodysplastic syndromes.
[15241818] Cancer 101(2): 226-41 (2004)
1999  
9
The treatment of the myelodysplastic syndromes.
[10570410] Cancer 86(10): 1893-9 (1999)
2008  
10
Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches.
[18813208] Cancer Control 15 Suppl(-): 40-9 (2008)
2010  
11
Iron overload in myelodysplastic syndromes: diagnosis and management.
[20125080] Cancer Control 17 Suppl(-): 2-8 (2010)
2009  
12
Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.
[20010512] Cancer Control 16 Suppl(-): 2-10 (2009)
2008  
13
Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes.
[18813207] Cancer Control 15 Suppl(-): 29-39 (2008)
2008  
14
Changing the treatment paradigm in myelodysplastic syndromes.
[18813206] Cancer Control 15 Suppl(-): 14-28 (2008)
2008  
15
Myelodysplastic syndromes: diagnosis and staging.
[18813205] Cancer Control 15 Suppl(-): 4-13 (2008)
2006  
16
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
[17242662] Cancer Control 13 Suppl(-): 12-6 (2006)
2006  
17
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
[17242661] Cancer Control 13 Suppl(-): 4-11 (2006)
2004  
18
Classification, treatment goals, and management principles for myelodysplastic syndromes.
[15625530] Cancer Control 11(6 Suppl): 3-6 (2004)
2001  
19
Myelodysplastic syndromes in the elderly.
[11176039] Cancer Control 8(1): 79-102 (2001)
2002  
20
Differentiation therapy for myelodysplastic syndrome.
[11948096] Clin Cancer Res 8(4): 939-41 (2002)
2007  
21
Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis.
[17962620] Oncologist 12(10): 1264-73 (2007)
1997  
22
Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
[9009082] Leukemia 11(2): 206-11 (1997)
2010  
23
Iron chelation therapy in myelodysplastic syndromes.
[20672005] Adv Hematol 2010(-): 756289 (2010)
2009  
24
Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review.
[19705430] Am J Hematol 84(10): 671-7 (2009)
2009  
25
Update on the therapy for myelodysplastic syndrome.
[19195035] Am J Hematol 84(3): 177-86 (2009)
2009  
26
Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
[19037863] Am J Hematol 84(1): 3-5 (2009)
2005  
27
Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
[16044436] Am J Hematol 79(4): 329-31 (2005)
2004  
28
Neutrophilic panniculitis with myelodysplastic syndromes presenting as pustulosis: case report and review of the literature.
[15114599] Am J Hematol 76(1): 61-5 (2004)
2000  
29
Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management.
[10706766] Am J Hematol 63(4): 212-22 (2000)
1992  
30
2008  
31
Myeloproliferative disorders.
[18779404] Blood 112(6): 2190-8 (2008)
2008  
32
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
[18401028] Blood 112(2): 231-9 (2008)
2008  
33
2008  
34
Telomere maintenance and human bone marrow failure.
[18239083] Blood 111(9): 4446-55 (2008)
2007  
35
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
[17488875] Blood 110(4): 1092-7 (2007)
2006  
36
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
[16609072] Blood 108(2): 419-25 (2006)
2009  
37
Defective ribosome biogenesis in myelodysplastic syndromes.
[19794078] Haematologica 94(10): 1336-8 (2009)
2008  
38
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
[18838480] Haematologica 93(11): 1712-7 (2008)
2008  
39
Myelodysplastic/myeloproliferative disorders.
[18166777] Haematologica 93(1): 4-6 (2008)
2006  
40
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
[17145595] Haematologica 91(12): 1596-604 (2006)
2005  
41
European consensus on grading bone marrow fibrosis and assessment of cellularity.
[16079113] Haematologica 90(8): 1128-32 (2005)
1998  
42
Diagnosis, classification, and cytogenetics of myelodysplastic syndromes.
[9573680] Haematologica 83(3): 258-75 (1998)
1998  
43
Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.
[9542325] Haematologica 83(1): 71-86 (1998)
1997  
44
The molecular basis of myelodysplastic syndromes.
[9175327] Haematologica 82(2): 191-204 (1997)
1995  
45
Myelodysplastic syndromes: the pediatric point of view.
[7672722] Haematologica 80(3): 268-79 (1995)
2008  
46
MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?
[19074057] Hematology Am Soc Hematol Educ Program -(-): 43-51 (2008)
2006  
47
Clinical issues in the management of patients with myelodysplasia.
[17124062] Hematology Am Soc Hematol Educ Program -(-): 205-10 (2006)
2006  
48
Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes.
[17124061] Hematology Am Soc Hematol Educ Program -(-): 199-204 (2006)
2004  
49
2003  
50
2002  
51
2001  
52
Immune pathology of myelodysplastic syndromes.
[11688840] Intern Med 40(10): 985-6 (2001)
1985  
53
Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.
[2999194] J Clin Pathol 38(11): 1201-17 (1985)
2006  
54
The myelodysplastic syndromes: diagnosis and treatment.
[16438486] Mayo Clin Proc 81(1): 104-30 (2006)
2005  
55
Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.
[15887439] Mayo Clin Proc 80(5): 681-98 (2005)
1989  
56
2004  
57
Focus on myeloproliferative diseases and myelodysplastic syndromes.
[15607959] Cancer Cell 6(6): 547-52 (2004)
1991  
58
An approach to dealing with mucosal damage.
[1999611] J Am Dent Assoc 122(2): 73-4 (1991)
2008  
59
Cytogenetic features in myelodysplastic syndromes.
[18414863] Ann Hematol 87(7): 515-26 (2008)
2008  
60
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
[18265982] Ann Hematol 87(5): 345-52 (2008)
2010  
61
Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
[20555069] Ann Oncol 21 Suppl 5(-): v158-61 (2010)
2007  
62
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
[17210514] Am J Clin Pathol 127(2): 197-205 (2007)
2009  
63
Myelodysplastic/myeloproliferative neoplasms.
[19605822] Am J Clin Pathol 132(2): 281-9 (2009)
2009  
64
2003  
65
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
[12623843] Blood 102(1): 43-52 (2003)
2003  
66
Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
[12506028] Blood 101(9): 3386-90 (2003)
2009  
67
How I treat patients with myelodysplastic syndromes.
[19383969] Blood 113(25): 6296-303 (2009)
2009  
68
Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
[19710499] Blood 114(26): 5251-5 (2009)
2011  
69
Myelodysplastic syndromes with bone marrow fibrosis.
[21282718] Haematologica 96(2): 180-3 (2011)
2011  
70
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
[21134982] Haematologica 96(3): 441-9 (2011)
2011  
71
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
[21357714] Haematologica 96(3): 349-52 (2011)
2011  
72
Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome.
[21810969] Haematologica 96(8): 1081-3 (2011)
2010  
73
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
[19773261] Haematologica 95(2): 303-10 (2010)
2007  
74
The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.
[17550842] Haematologica 92(6): 723-7 (2007)
2009  
75
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.
[19336747] Haematologica 94(4): 449-51 (2009)
2009  
76
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
[19546437] Haematologica 94(8): 1124-34 (2009)
2009  
77
Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.
[19644135] Haematologica 94(8): 1041-3 (2009)
2010  
78
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
[19850902] Haematologica 95(2): 340-2; author reply 343-4 (2010)
2004  
79
Childhood and adolescent lymphoid and myeloid leukemia.
[15561680] Hematology Am Soc Hematol Educ Program -(-): 118-45 (2004)
2010  
80
2010  
81
Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
[21239819] Hematology Am Soc Hematol Educ Program 2010(-): 357-62 (2010)
2010  
82
How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.
[21239812] Hematology Am Soc Hematol Educ Program 2010(-): 314-21 (2010)
2010  
83
Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
[21239814] Hematology Am Soc Hematol Educ Program 2010(-): 325-9 (2010)
2007  
84
2008  
85
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
[19074076] Hematology Am Soc Hematol Educ Program -(-): 166-75 (2008)
2008  
86
Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
[19074059] Hematology Am Soc Hematol Educ Program -(-): 60-7 (2008)
2009  
87
The changing classification of myelodysplastic syndromes: what's in a name?
[20008250] Hematology Am Soc Hematol Educ Program -(-): 645-55 (2009)
2009  
88
Treatment of MDS: something old, something new, something borrowed...
[20008251] Hematology Am Soc Hematol Educ Program -(-): 656-63 (2009)
2009  
89
Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
[20008252] Hematology Am Soc Hematol Educ Program -(-): 664-72 (2009)
2008  
90
New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?
[19112734] Blood Transfus 6(4): 191-8 (2008)
2010  
91
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
[20507806] Health Technol Assess 14 Suppl 1(-): 69-74 (2010)
2009  
92
Managing myelodysplastic symptoms in elderly patients.
[19966910] Clin Interv Aging 4(-): 413-23 (2009)
2010  
93
Standards and impact of hematopathology in myelodysplastic syndromes (MDS).
[21317447] Oncotarget 1(7): 483-96 (2010)
2010  
94
Safety and efficacy of azacitidine in myelodysplastic syndromes.
[20957213] Drug Des Devel Ther 4(-): 221-9 (2010)
2011  
95
Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature.
[21487529] Int J Clin Exp Pathol 4(3): 322-6 (2011)
2011  
96
Rational therapeutic options for patients with myeloproliferative neoplasms.
[21686205] Trans Am Clin Climatol Assoc 122(-): 11-26 (2011)
2010  
97
Therapy-related myelodysplastic syndrome: models and genetics.
[19857585] Biol Blood Marrow Transplant 16(1 Suppl): S45-7 (2010)
2010  
98
2009  
99
2009  
100
Iron overload in myelodysplastic syndromes.
[21082962] Expert Rev Hematol 2(3): 215-8 (2009)
2010  
101
Epigenetic changes in the myelodysplastic syndrome.
[20359628] Hematol Oncol Clin North Am 24(2): 317-30 (2010)
2010  
102
Mouse models of myelodysplastic syndromes.
[20359631] Hematol Oncol Clin North Am 24(2): 361-75 (2010)
2009  
103
Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention.
[19327589] Hematol Oncol Clin North Am 23(2): 361-76 (2009)
2010  
104
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
[20428194] Leukemia 24(6): 1128-38 (2010)
2008  
105
Management of myelodysplastic syndromes: 2008 update.
[19086598] Oncology (Williston Park) 22(12): 1344-52 (2008)
2006  
106
Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology.
[17220579] J Nihon Med Sch 73(6): 300-7 (2006)
2011  
107
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
[21189329] Cancer Res 71(3): 955-63 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



Search PubMed and many other databases on the combined search terms

GG: mds
GG: myelodysplastic syndrome

  • Myelodysplastisches Syndrom

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia